¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Genes and function."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • survival function
    »ýÁ¸ÇÔ¼ö
  • vegetative function
    ÀÚÀ²±â´É
  • vestibular function test
    ¾È¶ã±â´É°Ë»ç, ÀüÁ¤±â´É°Ë»ç
  • visuoperceptual function assessment
    ½Ã°¢Áö°¢±â´ÉÆò°¡
  • vital function
    »ý¸í±â´É
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • isomeric function
    À̼ºÁúü±â´É
  • municipal health function
    µµ½Ãº¸°Ç±â´É
  • phonatory function
    ¹ß¼º±â´É
  • reflex function
    ¹Ý»ç±â´É
  • somatosensory function
    ¸ö°¨°¢±â´É
  • survival function
    »ýÁ¸ÇÔ¼ö
  • vegetative function
    Áõ½Ä´É
  • vital function
    »ý¸í±â´É
  • liver function test
    °£±â´É°Ë»ç
  • pulmonary function test
    Æó±â´É°Ë»ç
  • renal function test
    ÄáÆÏ±â´É°Ë»ç, ½ÅÀå±â´É°Ë»ç
  • respiratory function test
    È£Èí±â´É°Ë»ç
  • righting function test
    ¹Ù·Î¼­±â±â´É°Ë»ç
  • vestibular function test
    ÀüÁ¤±â´É°Ë»ç, ¾È¶ã±â´É°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • gray matter (nuclei and columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
  • half and half nail
    ¹Ý¹Ý Á¶°©
  • hand and foot disease
    ¼ö Á· Áúȯ£¨â¢ðëòðü´£©£¬¼Õ ¹ß º´, ¼ö Á· º´ (â¢ðëÜ»).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ)
  • heat and acetic acid test
    °¡¿Â¾Æ¼¼Æ®»ê½ÃÇè (¹ý)(ʥ计­ß«ãËúÐÛö).
  • hereditary motor and sensory neuropathy
    À¯Àü¼º¿îµ¿ °¨°¢½Å°æº´Áõ
  • incision and drainage
    Àý°³¹è³ó(ü°³¹è³ó).
  • personality, anxious and fearful
    ºÒ¾È°øÆ÷¼º ÀΰÝ
  • pharmacy and therapeutic committee
    ¾à»çÀÇ·áÀ§¿øÈ¸(ËâË×ËöËíËôËôÌ·) º´¿ø(ËÓ Ëô)ÀÇ .
  • pneumocyte, types i and ii
    ÆóÆ÷¼¼Æ÷(øËøàá¬øà), IÇü°ú IIÇü
  • porokeratotoic eccrine ostial and dermal duct nevus
    ÇѰø°¢È­Áõ¼º ¿¡Å©¸°±¸¸Û ¹× ÁøÇǰü¸ð¹Ý
  • positional and postural vertigo
    µÎÀ§ ¹× üÀ§ º¯È¯(¼º) Çö±â
  • pruritic urticarial papules and plaqes of pregnany
    ÀӽŠ¼Ò¾ç¼º µÎµå·¯±â¼º ±¸Áø ¹× ÆÇ
  • pulmonary congestion and edema
    Æó¿ïÇ÷(øËê¦úì) ¹× ÆóºÎÁ¾(øËÝ©ðþ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hyperexcitability of vestibular function
    ÀüÁ¤±â´É°ú¹Î
  • hyperexcitability of vestibular function
    ÀüÁ¤±â´É°ú¹Î(îñïÔѦÒöΦÚÂ).
  • immunologic function
    ¸é¿ª±â´É.
  • isomeric function
    À̼º±â´É(¡­Ñ¦Òö).
  • kidney function test
    ½Å±â´É½ÃÇè(ãìѦÒöãËúÐ).
  • labyrinthine function
    ¹Ì·Î±â´É(¡­Ñ¦Òö).
  • labyrinthine function
    ¹Ì·Î±â´É
  • linear function
    ÀÏÂ÷ÇÔ¼ö(Ëö̤̰Ëà).
  • liver function test
    °£±â´É°Ë»ç(ÊÜѦÒöËþÞÛ).
  • localization of function
    ±â´É±¹Àç(ѦÒöÏÑî¤).
  • logarithmic function
    ·Î±×ÇÔ¼ö(ÊṴ̀Ëà).
  • metabolic function
    ´ë»ç±â´É(¡­Ñ¦Òö).
  • mixed function oxidase
    È¥ÇÕ±â´É¿Á½Ãµ¥À̽º.
  • mixed function oxidase
    º¹ÇÕ±â´É»êÈ­È¿¼Ò(ÜÜùêѦÒöß«ûùý£áÈ).
  • moment generating function
    Àû·ü¸ðÇÔ¼ö, ¸ð¸àÆ®¸ðÇÔ¼ö(¡­Ù½ùÞâ¦).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
RFT Renal Function Test
TB, Tb TuBerculosis; °áÇÙ
  = Tbc
  ? CIX of Op
    1. Pulm...
AIRF alterations in respiratory function
ALFT abnormal liver function test
COG center of gravity; cognitive function tests
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HRTF head-related transfer function
IIEF International Index of Erectile Function
LVF Left Ventricular Function
LVDF Left ventricular diastolic function
LFA-1 Leukocyte Function Antigen-1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • communication codes and characteristics
    È­ÀÇ ºÎÈ£¿Í ¼ºÁú
  • congenital and developmental bone disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º °ñ Àå¾Ö
  • congenital and developmental muscle disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º ±ÙÀå¾Ö
    Ãâ»ý ½ÃºÎÅÍ ±ÙÀúÇϸ¦ ³ªÅ¸³»°í Èå´ÃÈå´ÃÇÑ ¾ÆÀÌ. flo
  • connective tissue sheath of Key and Retzius
    Ű-·¹Ä¡¿ì½ºÀÇ °áÇÕ Á¶Á÷ ÃÊ
    ½Å°æ³»¸·, ƯÈ÷ ½Å°æ¼¶À¯ Á¾¸»Áö ÁÖÀ§ÀÇ ¾ãÀº ¿¬Àå.
  • crown and loop space maintainer
    Å©¶ó¿î¿£µå ·çÇÁÇü °£°Ý À¯Áö ÀåÄ¡
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
  • D and C ÀÚ±ÃÀÇ °æºÎ È®Àå°ú ³»¸· ¼ÒÆÄ.

    D factor

    D-ÀÎÀÚ
  • development of speech and language
    ÀÇ»ç ¼ÒÅëÀÇ ¹ß´Þ
  • ear nose and throat
    À̺ñÀÎÈİú
    ÈĵÎ, ºñ°­, ÀεΠµîÀ» Àü¹®À¸·Î ÇÏ´Â ÀÇÇÐÀÇ ÇÑ ºÐ°ú.
  • exostosis and osteoma
    ¿Ü°ñÁõ ¹× °ñÁ¾
    »À Á¶Á÷ÀÇ °ú¹ßÀ°Àº Åë»ó ¿ì¿¬È÷ ¹ß°ßµÇ´Â °ÍÀÌ ´ëºÎºÐÀÌ°í °¡²û ÀÓ»óÀûÀ¸·Î Àǹ̰¡ ÀÖ´Â °æ¿ì¸¦ º»´Ù. ÀÓ»óÀûÀ¸·Î ÇǺηΠµ¤Èù µÕ±Ù °ñ Á¶Á÷ÀÌ ¿ÜÀ̵µÀÇ ³»Ãø¿¡¼­ °í¸·À» °¡¸®¸ç °üÂûµÈ´Ù. ÀϺο¡ ±¹ÇÑµÈ ´ÜÀÏÀÇ °ñÁ¾Àº ¿ÜÀ̵µ¸¦ ¿ÏÀüÈ÷ ¸·°Å³ª °¨¿°À» ÀÏÀ¸Å°Áö ¾Ê´Â ÇÑ ¹®Á¦°¡ ¾øÀ¸³ª ¶§·Î Â÷°¡¿î ¹°¿¡ Áö¼ÓÀûÀ¸·Î ³ëÃâµÈ °ÍÀÌ ¿øÀÎÀ¸·Î Áö¸ñµÇ±âµµ ÇÏ´Â ´Ù¹ß¼º °ñÁ¾ÀÇ °æ¿ì´Â Á¡Â÷ ÁøÇàµÇ¾î ¼ö¼úÀÌ ÇÊ¿äÇϱ⵵ ÇÏ´Ù.
  • explosion and fire hazard
    Æø¹ß ÀÎÈ­¼º À§Çè
  • Food and Drug Administration
    ½ÄǰÀǾà±â±¸
  • H and D curve
    Ư¼º °î¼±
  • habit and impulse disorder
    ½À°ü ¹× Ãæµ¿ Àå¾Ö, ½À°ü ¹× Ãæµ¿º´
  • hand and foot disease
    ¼Õ¹ß º´, ¼öÁ· º´
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
genes, bacterial The genetic material of bacteria.
(12 Dec 1998)
genes, bcl-1 The B-cell leukaemia/lymphoma-1 genes, associated with various neoplasms when overexpressed. Overexpression results from the t(11;14) translocation, which is characteristic of mantle zone-derived B-cell lymphomas. The human c-bcl-1 gene is located at 11q13 on the long arm of chromosome 18.
(12 Dec 1998)
genes, bcl-2 The B-cell leukaemia/lymphoma-2 genes, responsible for blocking apoptosis in normal cells, and associated with follicular lymphoma when overexpressed. Overexpression results from the t(14;18) translocation. The human c-bcl-2 gene is located at 18q24 on the long arm of chromosome 18.
(12 Dec 1998)
genes, BRCA1 Tumour suppressor genes located on human chromosome 17q12-21. The mutation of these genes is associated with the formation of familial breast and ovarian cancer.
(12 Dec 1998)
genes, breast cancer susceptibility Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. Howeverm, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. See related entries to: BRCA1; BRCA2; Breast cancer, familial.
(12 Dec 1998)
genes, cdc Genes that code for proteins that regulate the cell division cycle. These genes form a regulatory network that culminates in the onset of mitosis by activating the p34cdc2 protein (protein p34cdc2).
(12 Dec 1998)
genes, dcc Tumour suppressor genes located in the 18q21-qter region of human chromosome 18. The absence of these genes is associated with the formation of colourectal cancer (dcc stands for deleted in colourectal cancer). The products of these genes show significant homology to neural cell adhesion molecules and other related cell surface glycoproteins.
(12 Dec 1998)
genes, dominant Genes that are reflected in the phenotype both in the homozygous and the heterozygous state.
(12 Dec 1998)
genes, env DNA sequences that form the coding region for the viral envelope (env) proteins in retroviruses. The env genes contain a cis-acting RNA target sequence for the rev protein (= gene products, rev), termed the rev-responsive element (rre).
(12 Dec 1998)
genes, erba Retrovirus-associated DNA sequences (erythroblastosis virus, avian, hence erba) originally isolated from the avian erythroblastosis virus. The c-erba proto-oncogene encodes the thyroid hormone receptors (receptors, thyroid hormone). Two distinct c-erba proto-oncogenes have been identified, erba-alpha and erba-beta, each giving rise to at least two proteins. Erba-alpha is located at 17q21 on the long arm of chromosome 17. Erba-beta is located at 3p24 on the short arm of chromosome 3. The v-erba oncogene potentiates cell transformation through inhibition of spontaneous differentiation of cells already transformed by the v-erbb gene and eliminates growth requirements of transformed erythroblasts.
(12 Dec 1998)
genes, erbb Retrovirus-associated DNA sequences (erbb) originally isolated from, or related to, the avian erythroblastosis virus (aev). These genes code for the epidermal growth factor receptor (egfr) family of receptors which is important in the control of normal cell proliferation and in the pathogenesis of human cancer. The genes include erbb-1 (genes, erbb-1), erbb-2 (genes, erbb-2), and erbb-3, all of which show abnormalities of expression in various human neoplasms.
(12 Dec 1998)
genes, erbb-1 Retrovirus-associated DNA sequences (erbb) originally isolated from the avian erythroblastosis virus (aev). The oncogene v-erbb arose by insertion of viral DNA into the c-erbb-1 proto-oncogene resulting in expression of a protein lacking the amino-terminal ligand-binding domain. V-erbb is the primary transforming gene of aev and abrogates the requirements for other mitogens. The proto-oncogene c-erbb-1 codes for the protein epidermal growth factor receptor (epidermal growth factor receptor-urogastrone). Overexpression of the gene occurs in a wide range of tumours, commonly squamous carcinomas of various sites and less commonly adenocarcinomas. The human c-erbb-1 gene is located at 7p12-13 on the short arm of chromosome 7.
(12 Dec 1998)
genes, erbb-2 Retrovirus-associated DNA sequences (erbb) related to the c-erbb-1 gene and identified by probes from c-erbb-1 or its avian viral homologue v-erbb. The proto-oncogene erbb-2 (c-erbb-2) codes for a protein that has structural features indicative of a growth factor receptor with close similarity to the epidermal growth factor (egf) receptor. Overexpression and amplification of the gene is associated with adenocarcinomas and with poor prognosis in breast carcinomas. The human c-erbb-2 gene is located at 17p12-21 on the short arm of chromosome 17.
(12 Dec 1998)
genes, fms Family of retrovirus-associated DNA sequences (fms) originally isolated from the susan mcdonough strain of feline sarcoma virus (sm-fesv). The proto-oncogene fms (c-fms) codes for a protein (csf-1) that is a member of the transmembrane tyrosine kinase growth factor receptor family. The human c-fms gene is located at 5q33.3 on the long arm of chromosome 5.
(12 Dec 1998)
genes, fos Retrovirus-associated DNA sequences (fos) originally isolated from the finkel-biskis-jinkins (fbj-msv) and finkel-biskis-reilly (fbr-msv) murine sarcoma viruses. The proto-oncogene protein c-fos codes for a nuclear protein which is involved in growth-related transcriptional control. The insertion of c-fos into fbj-msv or fbr-msv induces osteogenic sarcomas in mice. The human c-fos gene is located at 14q21-31 on the long arm of chromosome 14.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Economic and Social Council
    =ECOSOC
  • Food and Agriculture Organization
    (À¯¿£) ½Ä·® ³ó¾÷ ±â±¸
  • Food and Drug Administration
    ½Äǰ ÀǾ౹(º¸°Ç ±³À° º¹Áö¼ºÀÇ ÀϺÎ)
  • Foreign and Commonwealth Office
    ¿Ü¹« ¿¬¹æ¼º
  • Gog and Magog
    °î°ú ¸¶°î(»çÅÁ¿¡ ¹ÌȤµÇ¾î ÇÏ´Ã ³ª¶ó¿¡ ´ëÇ×ÇÏ´Â µÎ³ª¶ó)
  • H and C
    Çì·ÎÀÎ(heroin)°ú ÄÚÄ«ÀÎ(cocaine)À» ¼¯Àº °Í
  • Hereford and Worcester
    À×±Û·£µå ¼­ºÎÀÇ ÁÖ(1974³â ½Å¼³)
  • International Bank for Reconstruction and Development
    ±¹Á¦ ºÎÈï°³¹ßÀºÇà(IBRD)ÅëĪ(the world bank)
  • Jekyll and Hyde
    2ÁßÀΰÝÀÚÀÇ;2Áß ÀΰÝÀûÀÎ
  • Punch and Judy
    Àͻ콺·¯¿î ¿µ±¹ÀÇ ÀÎÇü±Ø
  • R&D,R.and D.
    research and development ¿¬±¸ °³¹ß
  • Royal and Ancient
    ·Î¿­ ¾Øµå ¿¡ÀÎ¼ÇÆ® °ñÇÁ Ŭ·´(¼¼°è ÃÖ°í,1754³â °³¼³)
  • Trinidad and Tobago
    ¼­Àεµ Á¦µµ¿¡ ÀÖ´Â ¿µ¿¬¹æ³»ÀÇ µ¶¸³±¹
  • and
    ±×¸®°í;¹×;¶ÇÇÑ;±×·¯ÀÚ;±×·¯¸é;(and/or=and or(newspapers and/or magazines ½Å¹® ¹× ¶Ç´Â ÀâÁö)
  • bait and switch
    À¯ÀÎ »ó¼úÀÇ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á